Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis

Kirk Hevener, Shahila Mehboob, Teuta Boci, Kent Truong, Bernard D. Santarsiero, Michael E. Johnson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The rapid rise in bacterial drug resistance coupled with the low number of novel antimicrobial compounds in the discovery pipeline has led to a critical situation requiring the expedient discovery and characterization of new antimicrobial drug targets. Enzymes in the bacterial fatty acid synthesis pathway, FAS-II, are distinct from their mammalian counterparts, FAS-I, in terms of both structure and mechanism. As such, they represent attractive targets for the design of novel antimicrobial compounds. Enoyl-acyl carrier protein reductase II, FabK, is a key, rate-limiting enzyme in the FAS-II pathway for several bacterial pathogens. The organism, Porphyromonas gingivalis, is a causative agent of chronic periodontitis that affects up to 25% of the US population and incurs a high national burden in terms of cost of treatment. P. gingivalis expresses FabK as the sole enoyl reductase enzyme in its FAS-II cycle, which makes this a particularly appealing target with potential for selective antimicrobial therapy. Herein we report the molecular cloning, expression, purification and characterization of the FabK enzyme from P. gingivalis, only the second organism from which this enzyme has been isolated. Characterization studies have shown that the enzyme is a flavoprotein, the reaction dependent upon FMN and NADPH and proceeding via a Ping-Pong Bi-Bi mechanism to reduce the enoyl substrate. A sensitive assay measuring the fluorescence decrease of NADPH as it is converted to NADP+ during the reaction has been optimized for high-throughput screening. Finally, protein crystallization conditions have been identified which led to protein crystals that diffract x-rays to high resolution.

Original languageEnglish (US)
Pages (from-to)100-108
Number of pages9
JournalProtein Expression and Purification
Volume85
Issue number1
DOIs
StatePublished - Sep 1 2012

Fingerprint

Porphyromonas gingivalis
Oxidoreductases
Enzymes
NADP
Bacterial Drug Resistance
Acyl Carrier Protein
Flavin Mononucleotide
Flavoproteins
Chronic Periodontitis
Molecular Cloning
Crystallization
Health Care Costs
Proteins
Fatty Acids
Fluorescence
X-Rays
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Biotechnology

Cite this

Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis. / Hevener, Kirk; Mehboob, Shahila; Boci, Teuta; Truong, Kent; Santarsiero, Bernard D.; Johnson, Michael E.

In: Protein Expression and Purification, Vol. 85, No. 1, 01.09.2012, p. 100-108.

Research output: Contribution to journalArticle

Hevener, Kirk ; Mehboob, Shahila ; Boci, Teuta ; Truong, Kent ; Santarsiero, Bernard D. ; Johnson, Michael E. / Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis. In: Protein Expression and Purification. 2012 ; Vol. 85, No. 1. pp. 100-108.
@article{cc1585f8eeac4cb48a0ef7e72bfba1b9,
title = "Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis",
abstract = "The rapid rise in bacterial drug resistance coupled with the low number of novel antimicrobial compounds in the discovery pipeline has led to a critical situation requiring the expedient discovery and characterization of new antimicrobial drug targets. Enzymes in the bacterial fatty acid synthesis pathway, FAS-II, are distinct from their mammalian counterparts, FAS-I, in terms of both structure and mechanism. As such, they represent attractive targets for the design of novel antimicrobial compounds. Enoyl-acyl carrier protein reductase II, FabK, is a key, rate-limiting enzyme in the FAS-II pathway for several bacterial pathogens. The organism, Porphyromonas gingivalis, is a causative agent of chronic periodontitis that affects up to 25{\%} of the US population and incurs a high national burden in terms of cost of treatment. P. gingivalis expresses FabK as the sole enoyl reductase enzyme in its FAS-II cycle, which makes this a particularly appealing target with potential for selective antimicrobial therapy. Herein we report the molecular cloning, expression, purification and characterization of the FabK enzyme from P. gingivalis, only the second organism from which this enzyme has been isolated. Characterization studies have shown that the enzyme is a flavoprotein, the reaction dependent upon FMN and NADPH and proceeding via a Ping-Pong Bi-Bi mechanism to reduce the enoyl substrate. A sensitive assay measuring the fluorescence decrease of NADPH as it is converted to NADP+ during the reaction has been optimized for high-throughput screening. Finally, protein crystallization conditions have been identified which led to protein crystals that diffract x-rays to high resolution.",
author = "Kirk Hevener and Shahila Mehboob and Teuta Boci and Kent Truong and Santarsiero, {Bernard D.} and Johnson, {Michael E.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.pep.2012.07.003",
language = "English (US)",
volume = "85",
pages = "100--108",
journal = "Protein Expression and Purification",
issn = "1046-5928",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis

AU - Hevener, Kirk

AU - Mehboob, Shahila

AU - Boci, Teuta

AU - Truong, Kent

AU - Santarsiero, Bernard D.

AU - Johnson, Michael E.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The rapid rise in bacterial drug resistance coupled with the low number of novel antimicrobial compounds in the discovery pipeline has led to a critical situation requiring the expedient discovery and characterization of new antimicrobial drug targets. Enzymes in the bacterial fatty acid synthesis pathway, FAS-II, are distinct from their mammalian counterparts, FAS-I, in terms of both structure and mechanism. As such, they represent attractive targets for the design of novel antimicrobial compounds. Enoyl-acyl carrier protein reductase II, FabK, is a key, rate-limiting enzyme in the FAS-II pathway for several bacterial pathogens. The organism, Porphyromonas gingivalis, is a causative agent of chronic periodontitis that affects up to 25% of the US population and incurs a high national burden in terms of cost of treatment. P. gingivalis expresses FabK as the sole enoyl reductase enzyme in its FAS-II cycle, which makes this a particularly appealing target with potential for selective antimicrobial therapy. Herein we report the molecular cloning, expression, purification and characterization of the FabK enzyme from P. gingivalis, only the second organism from which this enzyme has been isolated. Characterization studies have shown that the enzyme is a flavoprotein, the reaction dependent upon FMN and NADPH and proceeding via a Ping-Pong Bi-Bi mechanism to reduce the enoyl substrate. A sensitive assay measuring the fluorescence decrease of NADPH as it is converted to NADP+ during the reaction has been optimized for high-throughput screening. Finally, protein crystallization conditions have been identified which led to protein crystals that diffract x-rays to high resolution.

AB - The rapid rise in bacterial drug resistance coupled with the low number of novel antimicrobial compounds in the discovery pipeline has led to a critical situation requiring the expedient discovery and characterization of new antimicrobial drug targets. Enzymes in the bacterial fatty acid synthesis pathway, FAS-II, are distinct from their mammalian counterparts, FAS-I, in terms of both structure and mechanism. As such, they represent attractive targets for the design of novel antimicrobial compounds. Enoyl-acyl carrier protein reductase II, FabK, is a key, rate-limiting enzyme in the FAS-II pathway for several bacterial pathogens. The organism, Porphyromonas gingivalis, is a causative agent of chronic periodontitis that affects up to 25% of the US population and incurs a high national burden in terms of cost of treatment. P. gingivalis expresses FabK as the sole enoyl reductase enzyme in its FAS-II cycle, which makes this a particularly appealing target with potential for selective antimicrobial therapy. Herein we report the molecular cloning, expression, purification and characterization of the FabK enzyme from P. gingivalis, only the second organism from which this enzyme has been isolated. Characterization studies have shown that the enzyme is a flavoprotein, the reaction dependent upon FMN and NADPH and proceeding via a Ping-Pong Bi-Bi mechanism to reduce the enoyl substrate. A sensitive assay measuring the fluorescence decrease of NADPH as it is converted to NADP+ during the reaction has been optimized for high-throughput screening. Finally, protein crystallization conditions have been identified which led to protein crystals that diffract x-rays to high resolution.

UR - http://www.scopus.com/inward/record.url?scp=84864512716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864512716&partnerID=8YFLogxK

U2 - 10.1016/j.pep.2012.07.003

DO - 10.1016/j.pep.2012.07.003

M3 - Article

VL - 85

SP - 100

EP - 108

JO - Protein Expression and Purification

JF - Protein Expression and Purification

SN - 1046-5928

IS - 1

ER -